Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...
MarketBeat on MSN

Dexcom maps G8 launch, coverage expansion and double-digit growth at investor day

Sell in May and Go Away-Starting With These 3 Stocks DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for ...
Insurancenewsnet.com

Dexcom Wins Access to Dexcom One for 100,000 People Living With Type 2 Diabetes

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those treating ...
San Diego Union-Tribune

San Diego’s Dexcom gets first FDA clearance for an over-the-counter wearable continuous glucose monitor

San Diego device maker Dexcom has received the first FDA clearance for a continuous glucose monitor that doesn’t require a doctor’s prescription. The U.S. Food and Drug Administration cleared Dexcom’s ...
Nasdaq

DexCom's (DXCM) G7 CGM Coverage Expanded for Quebec Residents

DexCom Inc. DXCM recently announced that its G7 Continuous Glucose Monitoring (CGM) System will be added to the Régie de l'assurance maladie du Québec (RAMQ) Public Prescription Drug Insurance Plan.
Hosted on MSN

Dexcom tops Q1 estimates, lifts profit outlook but keeps sales target

Dexcom posted first-quarter 2026 results ahead of Wall Street expectations, with revenue up 15% to $1.19 billion and adjusted EPS of $0.56. The company raised its operating and EBITDA margin outlooks ...